GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Price-to-Funds-From-Operations

Oculis Holding AG (FRA:CR5) Price-to-Funds-From-Operations : (As of Jun. 21, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Oculis Holding AG (FRA:CR5) Business Description

Industry
Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.